Daré Bioscience, Inc. (DARE)
| Market Cap | 29.66M +16.3% |
| Revenue (ttm) | 1.16M +4,366.5% |
| Net Income | -12.02M |
| EPS | -0.95 |
| Shares Out | 14.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,766 |
| Open | 2.010 |
| Previous Close | 2.020 |
| Day's Range | 1.970 - 2.095 |
| 52-Week Range | 1.270 - 9.190 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 9.67 (+388.38%) |
| Earnings Date | May 14, 2026 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto... [Read more]
Financial Performance
In 2025, Daré Bioscience's revenue was $1.03 million, an increase of 10429.36% compared to the previous year's $9,784. Losses were -$13.40 million, 230.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price target is $9.67, which is an increase of 388.38% from the latest price.
News
Daré Bioscience Transcript: AGM 2026
The meeting covered eight proposals, including director elections, auditor ratification, and amendments to the stock incentive plan. All proposals were approved, with no questions from stockholders.
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Dare Bioscience receives NIH funding award notice to advance DARE-HPV
Dare Bioscience (DARE) announced receipt of a Notice of Award from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, NIH, obligating the…
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 million Funding award milestone follows Daré's announcement last week of th...
Dare Bioscience initiates DARE-HPV clinical study
Dare Bioscience (DARE) announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal inser...
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. governm...
Daré Bioscience Earnings Call Transcript: Q1 2026
Transitioning to a revenue-generating phase, first product revenue is expected in June 2026, with strong clinical and commercial momentum across a robust women's health pipeline. Cash runway is limited, but diversified capital sources and positive clinical milestones support growth.
Daré Bioscience Quarterly report: Q1 2026
Daré Bioscience has published its Q1 2026 quarterly earnings report on May 14, 2026.
Daré Bioscience Earnings release: Q1 2026
Daré Bioscience released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 202...
Dare Bioscience reports positive interim Phase 3 results for Ovaprene
Dare Bioscience (DARE) announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating Ovaprene, its investigational monthly, hormone-free intravaginal contra...
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DI...
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience Earnings Call Transcript: Q4 2025
DARE to PLAY, a topical sildenafil cream, launched pre-fulfillment prescribing nationwide with revenue expected in Q2 2026. The pipeline includes multiple differentiated women's health products, supported by strong grant funding and disciplined capital management.
Daré Bioscience Annual report: Q4 2025
Daré Bioscience has published its Q4 2025 annual report on March 26, 2026.
Daré Bioscience Earnings release: Q4 2025
Daré Bioscience released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Daré Bioscience Slides: Q4 2025
Daré Bioscience has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts
On National Viagra Day, Women Finally Claim Their Turn:
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
Dare Bioscience receives NIH funding award notice for DARE-PTB1
Dare Bioscience (DARE) announced receipt of a revised Notice of Award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes…
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Aw...